Business
Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3
Caris’ molecular profiling platforms will help identify and characterize patients for Zentalis’ clinical studies investigating its targeted candidates NEW
About this update from Zentalis Pharmaceuticals, Inc.
[{"type":"text","content":"Caris’ molecular profiling platforms will help identify and characterize patients for Zentalis’ clinical studies investigating its targeted candidates\nNEW YORK and SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a strategic collaboration with Caris Life Sciences, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. Through this partnership, Caris will sequence individuals’ complete exome and transcriptome, leverage real-world data to help inform clinical development and help identify eligible patients for Zentalis’ clinical trials. Initially, Caris will assist in the recruiting efforts for Zentalis’ clinical trials investigating the Wee1 inhibitor, ZN-c3. “We are pleased to establish this collaboration with Caris, a pioneer in precision medicine and molecular science,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis. “We believe Caris’ unique and comprehensive profiling offerings combined with robust databases will enable us to optimize the development of our novel oncology therapeutics, as well as provide invaluable resources for patient recruitment.” “We are excited to partner with Zentalis to help advance the development of their promising oncology candidates,” said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris. “Our unique platforms will provide Zentalis with critical information and insights to empower their programs. Together, we are committed to delivering better treatment options to cancer patients and unlocking the promise of precision medicine.” Under the terms of the agreement, Zentalis retains full ownership of its therapeutic candidates. About Zentalis Pharmaceuticals Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-c5,...